The issue of asymmetrical growth in Specialised Biotechnology Firms in the USA and the UK
by Tomas Gabriel Bas, Jorge Niosi
International Journal of Biotechnology (IJBT), Vol. 9, No. 1, 2007

Abstract: There are over 5000 Specialised Biotechnology Firms (SBFs) in the world, out of which at least 1500 are in the USA, 400 in Canada, and a similar number in the UK. Within this group of SBFs rapid growth is concentrated in some 10% of the firms. This paper compares the growth patterns of SBFs in the USA and the UK, and with the previous results for Canada. These three countries represent nearly 50% of SBFs in the world. By combining several different databases, the paper reveals the determining factors of SBF growth in the two leading countries. Using correlation and logistic regressions for each country, we found that five factors (patents, the targeting of human health products and processes, the support of venture capital, R&D and marketing corporate alliances, and the search for world markets) explain most of the growth of these firms.

Online publication date: Fri, 26-Jan-2007

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com